Candoxatril: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{Short description|An overview of the drug Candoxatril}} | |||
{{Drugbox | |||
| image = Candoxatril.svg | |||
| image_size = 250px | |||
| image_alt = Structural formula of Candoxatril | |||
}} | |||
'''Candoxatril''' is a pharmaceutical compound that acts as a prodrug for [[candoxatrilat]], an inhibitor of the enzyme [[neutral endopeptidase]] (NEP). It has been studied for its potential therapeutic effects in conditions such as [[hypertension]] and [[heart failure]]. | |||
== | ==Mechanism of Action== | ||
Candoxatril is | Candoxatril is converted in the body to its active form, candoxatrilat, which inhibits the activity of neutral endopeptidase. NEP is an enzyme responsible for the breakdown of several vasoactive peptides, including [[atrial natriuretic peptide]] (ANP), [[bradykinin]], and [[endothelin]]. By inhibiting NEP, candoxatrilat increases the levels of these peptides, leading to vasodilation and increased natriuresis, which can help lower blood pressure and reduce cardiac workload. | ||
== | ==Pharmacokinetics== | ||
Candoxatril | Candoxatril is administered orally and is rapidly absorbed from the gastrointestinal tract. It undergoes first-pass metabolism to form candoxatrilat, which is the active metabolite responsible for its pharmacological effects. The bioavailability of candoxatrilat is influenced by factors such as food intake and liver function. | ||
== | ==Clinical Applications== | ||
Candoxatril has been investigated primarily for its potential use in treating hypertension and heart failure. By inhibiting NEP, it can enhance the effects of endogenous natriuretic peptides, leading to improved cardiovascular outcomes. However, its clinical use has been limited due to the development of more effective and safer alternatives. | |||
==Side Effects== | |||
* [[ | The use of candoxatril can be associated with several side effects, including [[hypotension]], [[dizziness]], and [[gastrointestinal disturbances]]. These side effects are generally related to its vasodilatory effects and the increase in circulating vasoactive peptides. | ||
* [[ | |||
==Research and Development== | |||
Research into candoxatril and other NEP inhibitors has provided valuable insights into the role of natriuretic peptides in cardiovascular health. Although candoxatril itself is not widely used, the concept of NEP inhibition has led to the development of other therapeutic agents, such as [[sacubitril]], which is used in combination with [[valsartan]] in the treatment of heart failure. | |||
==Related pages== | |||
* [[Neutral endopeptidase]] | |||
* [[Atrial natriuretic peptide]] | |||
* [[Hypertension]] | |||
* [[Heart failure]] | |||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category: | [[Category:Prodrugs]] | ||
[[Category: | [[Category:Cardiovascular drugs]] | ||
Latest revision as of 03:57, 13 February 2025
An overview of the drug Candoxatril
| Candoxatril | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Candoxatril is a pharmaceutical compound that acts as a prodrug for candoxatrilat, an inhibitor of the enzyme neutral endopeptidase (NEP). It has been studied for its potential therapeutic effects in conditions such as hypertension and heart failure.
Mechanism of Action[edit]
Candoxatril is converted in the body to its active form, candoxatrilat, which inhibits the activity of neutral endopeptidase. NEP is an enzyme responsible for the breakdown of several vasoactive peptides, including atrial natriuretic peptide (ANP), bradykinin, and endothelin. By inhibiting NEP, candoxatrilat increases the levels of these peptides, leading to vasodilation and increased natriuresis, which can help lower blood pressure and reduce cardiac workload.
Pharmacokinetics[edit]
Candoxatril is administered orally and is rapidly absorbed from the gastrointestinal tract. It undergoes first-pass metabolism to form candoxatrilat, which is the active metabolite responsible for its pharmacological effects. The bioavailability of candoxatrilat is influenced by factors such as food intake and liver function.
Clinical Applications[edit]
Candoxatril has been investigated primarily for its potential use in treating hypertension and heart failure. By inhibiting NEP, it can enhance the effects of endogenous natriuretic peptides, leading to improved cardiovascular outcomes. However, its clinical use has been limited due to the development of more effective and safer alternatives.
Side Effects[edit]
The use of candoxatril can be associated with several side effects, including hypotension, dizziness, and gastrointestinal disturbances. These side effects are generally related to its vasodilatory effects and the increase in circulating vasoactive peptides.
Research and Development[edit]
Research into candoxatril and other NEP inhibitors has provided valuable insights into the role of natriuretic peptides in cardiovascular health. Although candoxatril itself is not widely used, the concept of NEP inhibition has led to the development of other therapeutic agents, such as sacubitril, which is used in combination with valsartan in the treatment of heart failure.
